A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

• Status: Recruiting
• Trial end date: 2022-12-05
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate efficacy and safety of CKD-351

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical
• Treatments: Latanoprost

Criteria

Inclusion Criteria:

1. More than the age of 19 years old

2. Subjects who has primary open-angle glaucoma or ocular hypertension

3. Subjects who sign on an informed consent form willingly

Exclusion Criteria:

1. Subjects with intraocular pressure ≥ 35 mmHg at Visit 1 or Visit 2 (AM 09:00)

2. Subjects with a maximum corrected visual acuity ≤ 0.3 in the selected evaluation eye at Visit 1 or Visit 2

3. Subjects who were diagnosed as below

• Aphakia

• Intraocular lens

• Acute or Chronic Closed-Angle Glaucoma

• Secondary Glaucoma

4. Subjects with ocular inflammation or infection within the last 3 months

5. Subjects with significant history of ocular trauma during the last 6 months or who underwent surgical opthalmic surgery

6. Subjects who received topical or systemic steroids within the last 1 month.